Arena Pharmaceuticals Inc (ARNA.OQ)
11.39USD
4:00pm EDT
$2.51 (+28.27%)
$8.88
$9.00
$13.50
$8.52
19,836,356
45,363,220
$11.99
$1.23
ARNA.OQ
About
Overall
| Beta: | 0.15 |
| Market Cap (Mil.): | $1,615.13 |
| Shares Outstanding (Mil.): | 182.50 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARNA.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 40.79 | 43.38 |
| EPS (TTM): | -0.66 | -- | -- |
| ROI: | -49.68 | 8.90 | 9.53 |
| ROE: | -160.96 | 13.05 | 11.11 |
FDA OKs first obesity drug in 13 years
NEW YORK/WASHINGTON - U.S. health regulators approved the first new weight-loss drug in 13 years, allowing Arena Pharmaceuticals Inc to bring its Belviq pill to market as public health advocates push for new solutions to the nation's growing obesity epidemic.
Consumer group urges FDA to reject Arena diet drug
- Watchdog group Public Citizen urged U.S. regulators on Tuesday not to approve Arena Pharmaceuticals Inc's experimental diet pill lorcaserin, citing concerns it could increase patients' risk of heart valve damage.
Arena shares soar as experts recommend approval for obesity drug
- Shares of Arena Pharmaceuticals Inc nearly doubled in value after a panel of experts recommended approval of the company's obesity pill, a big step towards making it the first new diet drug on the U.S. market in more than a decade.
Arena obesity pill wins over U.S. advisers
SILVER SPRING, Maryland - An experimental obesity pill from Arena Pharmaceuticals Inc won the support of U.S. advisers on Thursday, as public health advocates push for new solutions to the nation's growing obesity epidemic. | Video
Arena obesity pill wins over U.S. advisers
SILVER SPRING, Maryland - An experimental obesity pill from Arena Pharmaceuticals Inc won the support of U.S. advisers on Thursday, as public health advocates push for new solutions to the nation's growing obesity epidemic.
US FDA staff focus on safety of Arena obesity pill
WASHINGTON - U.S. drug reviewers on Tuesday said Arena Pharmaceuticals Inc's obesity pill appeared to help people lose weight and was unlikely to cause tumors in humans, but questioned if the company had provided enough data to rule out heart problems.
FDA panel to discuss Arena obesity drug in 2nd quarter
- An FDA advisory committee will meet in the second quarter to discuss Arena Pharmaceutical Inc's experimental obesity drug following the company's recent resubmission of an application seeking its approval, Arena said on Wednesday.
Arena says addressed FDA concerns on weight loss drug
- Arena Pharmaceuticals Inc said on Tuesday it submitted data to health regulators that should squash cancer concerns tied to the company's experimental weight loss drug lorcaserin, and believes it will gain U.S. approval.
Arena responds to FDA concerns on weight loss drug
- Arena Pharmaceuticals Inc said on Tuesday it submitted an official response addressing safety concerns of U.S. health regulators over the company's experimental weight loss drug lorcaserin, and believes it will gain U.S. approval.
Competitors
| Price | Change | |
|---|---|---|
| Roche Holding Ltd. (ROG.VX) | CHF163.00 | +0.30 |
| GlaxoSmithKline plc (GSK.L) | 1,470.00p | -3.50 |
| VIVUS, Inc. (VVUS.OQ) | $28.33 | +1.94 |
| Orexigen Therapeutics, Inc. (OREX.OQ) | $4.92 | +0.83 |
Earnings vs 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Alpha Street Research
|
$16.00
|
|
Provider: Plunkett Research, Ltd.
|
$49.00
|
|
Provider: Market Edge
|
$46.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
